In addition, first-line gefitinib, an EGFR-TKI, is an effective and feasible treatment for elderly advanced NSCLC patients with activating mutations who were relatively ineligible for standard chemotherapy [7]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.